Data from EMA (European Medicines Agency) - Curated by Toby Galbraith - Last updated 11 July 2017

Indication(s)

Zurampic, in combination with a xanthine oxidase inhibitor, is indicated in adults for the adjunctive treatment of hyperuricaemia in gout patients (with or without tophi) who have not achieved target serum uric acid levels with an adequate dose of a xanthine oxidase inhibitor alone.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Hypogonadism

Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more.

Visit Hypogonadism

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

Visit Psoriasis

Related Content

More information

Category Value
Agency product number EMEA/H/C/003932
Orphan designation No
Date First Approved 18-02-2016
Type Medicinal product subject to medical prescription
Marketing authorisation holder Grünenthal GmbH